These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 22935466)

  • 1. The year in atherothrombosis.
    Sanz J; Moreno PR; Fuster V
    J Am Coll Cardiol; 2012 Sep; 60(10):932-42. PubMed ID: 22935466
    [No Abstract]   [Full Text] [Related]  

  • 2. Relationship between plasma homocysteine and the morphological and immunohistochemical study of carotid plaques in patients with carotid stenosis over 70%.
    Alvarez B; Yugueros X; Fernández E; Luccini F; Gené A; Matas M
    Ann Vasc Surg; 2012 May; 26(4):500-5. PubMed ID: 22520390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Prevention of cardiovascular disease].
    Rev Infirm; 2006 Mar; (119):16-23. PubMed ID: 16625779
    [No Abstract]   [Full Text] [Related]  

  • 4. Limits and perspective of oral therapy with statins and aspirin for the prevention of symptomatic cholesterol gallstone disease.
    Cariati A; Piromalli E
    Expert Opin Pharmacother; 2012 Jun; 13(9):1223-7. PubMed ID: 22607008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipids, atherosclerosis and CVD risk: is CRP an innocent bystander?
    Nordestgaard BG; Zacho J
    Nutr Metab Cardiovasc Dis; 2009 Oct; 19(8):521-4. PubMed ID: 19695857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A few unpleasant facts about atherosclerotic arterial disease in the United States and the world.
    Alpert JS
    Am J Med; 2012 Sep; 125(9):839-40. PubMed ID: 22938924
    [No Abstract]   [Full Text] [Related]  

  • 7. Guidelines in the USA, a viewpoint contrary to those guidelines in Europe, Canada, Britain and the International Atherosclerosis Society.
    Saraf S; Ray KK
    Curr Opin Lipidol; 2014 Dec; 25(6):413-7. PubMed ID: 25268983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Competing risk of atherosclerotic risk factors for arterial and venous thrombosis in a general population: the Tromso study.
    Brækkan SK; Hald EM; Mathiesen EB; Njølstad I; Wilsgaard T; Rosendaal FR; Hansen JB
    Arterioscler Thromb Vasc Biol; 2012 Feb; 32(2):487-91. PubMed ID: 22075253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. From pathophysiology to targeted therapy for atherothrombosis: a role for the combination of statin and aspirin in secondary prevention.
    Chapman MJ
    Pharmacol Ther; 2007 Jan; 113(1):184-96. PubMed ID: 17070923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The year in atherothrombosis.
    Sanz J; Fuster V
    J Am Coll Cardiol; 2011 Aug; 58(8):779-91. PubMed ID: 21835312
    [No Abstract]   [Full Text] [Related]  

  • 11. [Risk factors in central retinal vein occlusion].
    Călugăru D
    Oftalmologia; 2011; 55(2):27-37. PubMed ID: 21888066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Are we losing homocysteine as a cardiovascular risk factor?
    Bunout D; Hirsch S
    Nutrition; 2005 Oct; 21(10):1068-9. PubMed ID: 16157246
    [No Abstract]   [Full Text] [Related]  

  • 13. Drugs for lipids.
    Treat Guidel Med Lett; 2011 Mar; 9(103):13-20. PubMed ID: 21350395
    [No Abstract]   [Full Text] [Related]  

  • 14. [Osteoporosis and atherosclerosis].
    Omura Y; Nishio Y; Kashiwagi A
    Clin Calcium; 2007 Mar; 17(3):346-53. PubMed ID: 17339738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Residual risk and high-density lipoprotein cholesterol levels: is there a relationship?
    Shah PK
    Rev Cardiovasc Med; 2011; 12(2):e55-9. PubMed ID: 21796083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Residual risk for secondary ischemic events in patients with atherothrombotic disease: opportunity for future improvements in patient care.
    Pepine CJ
    Ann Med; 2010; 42(1):19-35. PubMed ID: 20092398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Homocysteine-lowering therapy for preventing atherothrombotic events: its role in high risk population.
    Acikel S; Dogan M; Akdemir R
    Int J Cardiol; 2010 Oct; 144(2):326-8. PubMed ID: 19324433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacotherapy of dyslipidemias in the adult population.
    Vigna GB; Fellin R
    Expert Opin Pharmacother; 2010 Dec; 11(18):3041-52. PubMed ID: 20958118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Combination pharmacotherapy therapy in the management of atherogenic dyslipidemia].
    Kłosiewicz-Latoszek L; Cybulska B
    Kardiol Pol; 2005 Jun; 62 Suppl 2():II76-80. PubMed ID: 19813341
    [No Abstract]   [Full Text] [Related]  

  • 20. Cardiovascular disease risk factors other than dyslipidemia. Executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan - 2012 version.
    Teramoto T; Sasaki J; Ishibashi S; Birou S; Daida H; Dohi S; Egusa G; Hiro T; Hirobe K; Iida M; Kihara S; Kinoshita M; Maruyama C; Ohta T; Okamura T; Yamashita S; Yokode M; Yokote K
    J Atheroscler Thromb; 2013; 20(10):733-42. PubMed ID: 23892529
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.